Medical Condition News

RSS

New research may shed light on possible treatments for prion diseases

New research by Chongsuk Ryou, researcher at the UK Sanders-Brown Center on Aging and professor of microbiology, immunology and molecular genetics in the UK College of Medicine, may shed light on possible treatments for prion diseases.

15 Mar 2011

Pico-Tesla receives ISO certification for Resonator device

Pico-Tesla, The Magneceutical Company, has received the International Organization for Standardization 13485:2003 certificate for the "design, development, production, manufacture and distribution of resonator systems that generate a low-level electromagnetic field for the therapeutic treatment of disease."

15 Mar 2011

Positive top-line results from IPX066 Phase III study in patients with PD

Impax Pharmaceuticals, the branded products division of Impax Laboratories, Inc., today announced statistically significant, positive, top-line results of the ADVANCE-Parkinson's Disease Phase III clinical study of the safety and efficacy of IPX066 versus immediate-release carbidopa-levodopa in advanced PD patients experiencing motor fluctuations.

15 Mar 2011

Bad jobs can make one mentally ill: Study

A latest study shows that a job that provides low control, high demands, complexity and the perception of unfair pay may lead to worse mental health than being unemployed. The study appeared in the journal Occupational Environmental Medicine.

14 Mar 2011

Baby Joseph’s flight to US from Canada

Baby Joseph Maraachli all of one year of age, is in a vegetative state with a severe neurological condition and will not recover, Canadian doctors say. His parents Moe Maraachli and Sana Nader, have transferred him to a US Catholic hospital after an Ontario court ruled doctors could remove a breathing tube keeping him alive. An Ontario hospital had refused his parents' request for a tracheotomy they say will prolong his life by six months and allow him to die at home. A Catholic hospital in the US city of St Louis will review his case, according to the family’s lawyer.

14 Mar 2011

Repligen reports positive results from RG1068 Phase 3 study to improve MRI of the pancreas

Repligen Corporation reported today positive top-line results from a Phase 3 study to evaluate the safety and efficacy of RG1068, synthetic human secretin, to improve magnetic resonance imaging (MRI) of the pancreas in patients with pancreatic disease using endoscopy (ERCP) as a diagnostic reference.

14 Mar 2011

Nanoscale whiskers could hold key to creating working human muscle tissue

Minute whiskers of nanoscale dimensions taken from sea creatures could hold the key to creating working human muscle tissue, University of Manchester researchers have discovered.

14 Mar 2011

OrbusNeich launches CE marked Azule Cobalt Chromium Stent

OrbusNeich today announced the launch of the CE marked Azule Cobalt Chromium Stent. The Azule Stent combines the proven stent design of its predecessor, the company's Blazer™ Cobalt Chromium Stent, with a delivery system with enhanced crossability and flexible deliverability.

14 Mar 2011

Euthymics Bioscience initiates EB-1010 phase 2b/3a TRIADE clinical trial for major depressive disorder

Euthymics Bioscience, Inc. today announced the initiation of an advanced clinical study of its lead product candidate EB-1010 for the treatment of major depressive disorder (MDD). The TRIADE (Triple Reuptake Inhibitor Anti-Depressant Effects) trial is a phase 2b/3a clinical trial designed to assess the safety and efficacy of EB-1010, a novel serotonin-preferring triple reuptake inhibitor.

14 Mar 2011

Medtronic launches Contour 3D Annuloplasty Ring for treatment of tricuspid valve disease

Medtronic, Inc. today announced the global launch of a new tricuspid ring for the treatment of tricuspid valve disease. Called the Contour 3D™ Annuloplasty Ring, the device is designed to restore normal valve function by remodeling the natural valve's shape and size. The Contour 3D Ring is approved for use in the U.S., Europe and several other countries.

14 Mar 2011

Majority of Americans fall short of vitamin D

Well-known for its role in keeping bones strong, vitamin D is now being hailed for so much more – from normal muscle function to a healthy immune system. Yet despite the growing research on the power of vitamin D, seven out of 10 Americans still fall short of the recommended vitamin D in their diets each day, according to the recent Dietary Guidelines Committee Advisory report.

14 Mar 2011

Positive results from azide drug-loaded Emulsiphan preclinical toxicity study

Cornerstone Pharmaceuticals, Inc., a leader in cancer metabolism-based therapeutics, today announced encouraging results of a preclinical toxicity study of azide drug-loaded Emulsiphan nano emulsions conducted with the National Cancer Institute (NCI) under a Collaboration Agreement. Emulsiphan is Cornerstone's proprietary nanoparticle drug delivery system.

14 Mar 2011

Biodel selects BIOD-105, BIOD-107 recombinant human insulin formulations for clinical testing, development

Biodel Inc. announced today that it has selected two new formulations of recombinant human insulin for clinical testing and is accelerating clinical development plans of these mealtime insulin drug candidates. The new formulations, BIOD-105 and BIOD-107, are designed to result in more rapid insulin action compared to currently marketed meal time insulin analogs while maintaining an injection site tolerability profile comparable to currently marketed insulins.

14 Mar 2011

KAI initiates enrollment in KAI-4169 Phase 2 study for secondary hyperparathyroidism

KAI Pharmaceuticals, Inc., a privately held drug discovery and development company, today announced enrollment of the first patients in a Phase 2 study of KAI-4169, a novel pharmaceutical agent being tested for the treatment of secondary hyperparathyroidism (SHPT), which is a frequent and serious complication of end-stage renal disease (ESRD).

14 Mar 2011

Researchers discover new gene for Sensenbrenner syndrome

Dutch researchers of the Radboud University Medical Center in Nijmegen found a new gene for Sensenbrenner syndrome (Journal of Medical Genetics, 2011 Mar 4). The mutation adds support to the hypothesis that defects in ciliar transport are the cause of the disease. Project leader Dr. Heleen H. Arts is supported by a Kolff Junior Postdoc Grant of the Dutch Kidney Foundation.

14 Mar 2011

Transcept initiates enrollment in TO-2061 Phase 2 study for treatment resistant obsessive compulsive disorder

Transcept Pharmaceuticals, Inc. today announced the first patient has been enrolled in a Phase 2 clinical study to evaluate TO-2061 as an adjunctive treatment for obsessive compulsive disorder (OCD) in patients who have responded inadequately to currently approved treatments. OCD affects 1 to 2 percent of the United States adult population and can significantly impair the lives of patients and their families.

14 Mar 2011

European Patent Office grants ProtAffin key patent for CellJammer discovery technology

ProtAffin AG, a biotechnology company developing novel biopharmaceuticals for respiratory disease, inflammation and oncology, today announced that it has been granted a key patent by the European Patent Office protecting its CellJammer® discovery technology, which enables the development of a new class of biopharmaceuticals.

14 Mar 2011

Omthera commences dosing in pivotal Epanova Phase III EVOLVE trial in patients with very high triglycerides

Omthera Pharmaceuticals, Inc., a privately-held emerging specialty pharmaceuticals company, announced today that the first patient has been dosed in its pivotal Phase III EVOLVE (EpanoVa fOr Lowering Very high triglyceridEs) trial for Epanova™, the Company's lead compound for the treatment of patients with very high triglycerides. Epanova is an Omega-3 fatty acid containing a novel formulation of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA).

14 Mar 2011

Anacor completes enrollment in AN2728 Phase 2b trial in psoriasis

Anacor Pharmaceuticals announced today that it has completed enrollment in its Phase 2b trial of AN2728, a topical anti-inflammatory product candidate for the treatment of psoriasis. Psoriasis is a chronic inflammatory skin disease that affects approximately 7.5 million people in the United States and over 100 million people worldwide.

14 Mar 2011

BioInvent commences BI-204 phase II study in patients with acute coronary syndrome

BioInvent International AB announces today the dosing of the first patient in the phase II study of the Company's antibody, BI-204. The product candidate is being developed for secondary prevention of cardiovascular events in patients with acute coronary syndrome.

14 Mar 2011

Medical Condition News

New research may shed light on possible treatments for prion diseases

Pico-Tesla receives ISO certification for Resonator device

Positive top-line results from IPX066 Phase III study in patients with PD

Bad jobs can make one mentally ill: Study

Baby Joseph’s flight to US from Canada

Repligen reports positive results from RG1068 Phase 3 study to improve MRI of the pancreas

Nanoscale whiskers could hold key to creating working human muscle tissue

OrbusNeich launches CE marked Azule Cobalt Chromium Stent

Euthymics Bioscience initiates EB-1010 phase 2b/3a TRIADE clinical trial for major depressive disorder

Medtronic launches Contour 3D Annuloplasty Ring for treatment of tricuspid valve disease

Majority of Americans fall short of vitamin D

Positive results from azide drug-loaded Emulsiphan preclinical toxicity study

Biodel selects BIOD-105, BIOD-107 recombinant human insulin formulations for clinical testing, development

KAI initiates enrollment in KAI-4169 Phase 2 study for secondary hyperparathyroidism

Researchers discover new gene for Sensenbrenner syndrome

Transcept initiates enrollment in TO-2061 Phase 2 study for treatment resistant obsessive compulsive disorder

European Patent Office grants ProtAffin key patent for CellJammer discovery technology

Omthera commences dosing in pivotal Epanova Phase III EVOLVE trial in patients with very high triglycerides

Anacor completes enrollment in AN2728 Phase 2b trial in psoriasis

BioInvent commences BI-204 phase II study in patients with acute coronary syndrome

The CAR T Veteran: A Journey of Resilience, Remission, and Advocacy

Innovating for impact: Jordi Labs on aligning methodologies with FDA expectation

Exploring the role of confocal-based high-content imaging in advancing core facilities

Latest News